Synthesis and Characterization of ULK1/2 Kinase Inhibitors That Inhibit Autophagy and Upregulate Expression of Major Histocompatibility Complex I for the Treatment of Non-Small Cell Lung Cancer
ACS Chemical Biology · 20.03.2026 · 21 (3) · 469-489
DOI: 10.1021/acschembio.5c00711 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Chemical Biology, online erschienen am 12.02.2026. Verfasst von Fabiana Izidro A L Layng und 20 weiteren Autor:innen. Beteiligte Einrichtung: Center for Therapeutics Discovery, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California 92037, Unit…. Hauptthemen laut MEDLINE: Autophagy, Carcinoma, Non-Small-Cell Lung, Autophagy-Related Protein-1 Homolog, Protein Kinase Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 63 Literaturangaben. Gefördert von: NCI NIH HHS, Janssen Research and Development, National Cancer Institute.
Abstract (Originalsprache)
Autophagy inhibition represents a promising therapeutic approach for the management of various cancers including nonsmall cell lung cancer (NSCLC). We previously reported SBP-7455, a dual inhibitor of unc-51-like kinase 1 (ULK1) and its homologue ULK2 and described its effects on triple-negative breast cancer (TNBC) cells. Herein we report the design, synthesis, and characterization of SBP-5147 and SBP-7501, two new dual ULK1/2 inhibitors that are cytotoxic against NSCLC cells, inhibit autophagic flux in A549 cells, and present greater oral exposure than SBP-7455 at a lower dose. In addition, SBP-5147 effectively modulates autophagy and increases the expression of major histocompatibility complex (MHC) class I in NSCLC cells, which may support the rationale for ULK1/2 inhibition as a strategy to overcome resistance to immunotherapy. Together these data support the use of ULK inhibitors as part of a cancer treatment strategy, either as a single agent or in combination with current therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Therapeutics Discovery, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California 92037, United States.
- Structural Genomics Consortium, Buchmann Institute for Molecular Life Sciences, Goethe-University Frankfurt, Frankfurt 60438, Germany.
- Institute of Pharmaceutical Chemistry, Goethe-University Frankfurt, Frankfurt 60438, Germany.
- Molecular and Cell Biology Laboratory, The Salk Institute for Biological Studies, La Jolla, California 92037, United States.
ORCID-Profile: Lester J Lambert, Jiaqian Wu, Apirat Chaikuad, Stefan Knapp, Guy S Salvesen, Nicholas D P Cosford
Förderung
- NCI NIH HHS
- Janssen Research and Development
- National Cancer Institute
- Bayer
- Genentech
- Takeda Pharmaceutical Company
- Pfizer
- Bristol-Myers Squibb
Zitieren
APA
Layng, F. I. A. L., Ren, H., Bakas, N. A., Panickar, D. R., Lambert, L. J., Celeridad, M., Wu, J., De Backer, L., Chandrachud, P., Limpert, A. S., Vamos, M., Chaikuad, A., Verdugo, B. B., Hagan, P. M., Brun, S. N., Tautz, L., Knapp, S., Shaw, R. J., Salvesen, G. S., …, & Cosford, N. D. P. (2026). Synthesis and Characterization of ULK1/2 Kinase Inhibitors That Inhibit Autophagy and Upregulate Expression of Major Histocompatibility Complex I for the Treatment of Non-Small Cell Lung Cancer. ACS Chemical Biology, 21(3), 469-489. https://doi.org/10.1021/acschembio.5c00711
Vancouver
Layng FIAL, Ren H, Bakas NA, Panickar DR, Lambert LJ, Celeridad M, et al. Synthesis and Characterization of ULK1/2 Kinase Inhibitors That Inhibit Autophagy and Upregulate Expression of Major Histocompatibility Complex I for the Treatment of Non-Small Cell Lung Cancer. ACS Chemical Biology. 2026;21(3):469-489. doi:10.1021/acschembio.5c00711
BibTeX
@article{Layng2026,
author = {Layng, Fabiana Izidro A L and Ren, Huiyu and Bakas, Nicole A and Panickar, Dhanya R and Lambert, Lester J and Celeridad, Maria and Wu, Jiaqian and De Backer, Laurent and Chandrachud, Preeti and Limpert, Allison S and Vamos, Mitchell and Chaikuad, Apirat and Verdugo, Betsaida B and Hagan, Patrick M and Brun, Sonja N and Tautz, Lutz and Knapp, Stefan and Shaw, Reuben J and Salvesen, Guy S and Sheffler, Douglas J and Cosford, Nicholas D P},
title = {Synthesis and Characterization of ULK1/2 Kinase Inhibitors That Inhibit Autophagy and Upregulate Expression of Major Histocompatibility Complex I for the Treatment of Non-Small Cell Lung Cancer},
journal = {ACS Chemical Biology},
year = {2026},
volume = {21},
number = {3},
pages = {469--489},
doi = {10.1021/acschembio.5c00711}
}
EUVIMED